Telo Genomics Announces Co-Authored Publication of a Prospective 5-year Multiple Myeloma Study - Successfully Identifying High Risk versus Low Risk Smoldering Myeloma Patients

About this update from Telo Genomics Corp.

[{"type":"text","content":"Telo Genomics Announces Co-Authored Publication of a Prospective 5-year Multiple Myeloma Study - Successfully Identifying High Risk versus Low Risk Smoldering Myeloma PatientsToronto, Ontario--(Newsfile Corp. - April 29, 2021) - Telo Genomics Corp. (TSXV: TELO) (the \"Company\" or \"TELO\") is pleased to announce that it has co-authored a publication demonstrating TELO's ability to identify high risk versus low-risk smoldering myeloma patients in a large longitudinal prospective multiple myeloma clinical study including 214 patients. The study was recently published in the Scientific Journal titled \"Cancers\".\"This study confirms the potential of TeloView® technology to fill an important unmet diagnostic/prognostic need for multiple myeloma and its precursors,\" said Guido Baechler, TELO's Chairman. \"We see now the potential to accelerate the transition of TeloView® tests towards commercialization.\"The patient groups included cohorts for the typical stages of the disease, form the least to the most advanced: monoclonal gammopathy of undetermined significance (MGUS) (n=54); smoldering multiple myeloma (SMM) (n=24) and multiple myeloma (MM) (n=136). All patient samples were assessed using Telo Genomics' proprietary technology platform TeloView®. Patients in the study were followed prospectively for up to 5 years.The most important result was the identification of high-risk SMM patients who progressed to active MM (symptomatic) within 1-3 years from point of diagnosis versus low risk stable SMM patients who remained at the smoldering stage (asymptomatic) for over 5 years with high significance. Moreover, TeloView® analysis identified MM patients with stable form of the disease versus those with aggressive form of the disease with high significance. Importantly, the quantification of TeloView® parameters correlated with MM patient's survival rate. Currently, there is no single clinical test that allows the identification of high risk versus low risk smoldering myeloma patients.The results of this study validate the findings of previously published MM clinical studies using TeloView® that were published in 2014 and 2019, with a total number of 362 patients analyzed to date across the three published clinical studies.Multiple myeloma is a highly challenging and deadly blood cancer that forms in plasma...

More updates from Telo Genomics Corp.